CorMedix Touts Q2 REZZAYO Data, Melinta Integration and DefenCath Reimbursement Shift at Conference [Yahoo! Finance]
CorMedix Inc. (CRMD)
NASDAQ:AMEX Investor Relations:
cormedix.com
Company Research
Source: Yahoo! Finance
primary endpoint of fungal-free survival at day 90, and management emphasizes potential differentiation on tolerability and discontinuation versus azole-based standard care while targeting a much larger prophylaxis market (~$500M for BMT and $2B total). Melinta integration and cash flow: The Melinta acquisition adds commercial scale and about $150 million of stable revenue to help offset CorMedix's exposure from DefenCath , which CMS is transitioning to bundled reimbursement in July—expected to depress reimbursement in Q3–Q4 before improvements in 2027. DefenCath commercialization and TPN timing : Management is pursuing Medicare Advantage uptake using real-world evidence (an interim analysis showing a reported 70% reduction in hospitalizations) as the largest untapped market, and now anticipates the TPN phase III study could complete in early 2027 with enrollment just under 30%. Interested in CorMedix Inc? Here are five stocks we like better. High Risk, High Reward: 3 Healthca
Show less
Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRMD alerts
High impacting CorMedix Inc. news events
Weekly update
A roundup of the hottest topics
CRMD
News
- CorMedix CEO touts Melinta pivot, DefenCath TDAPA transition and Q2 REZZAYO Phase 3 data at Leerink [Yahoo! Finance]Yahoo! Finance
- CorMedix (CRMD) had its "outperform" rating reaffirmed by Leerink Partners.MarketBeat
- Assessing CorMedix (CRMD) Valuation After Recent Share Price Weakness And Growth Expectations [Yahoo! Finance]Yahoo! Finance
- CorMedix (CRMD) had its price target lowered by Needham & Company LLC from $15.00 to $14.00. They now have a "buy" rating on the stock.MarketBeat
- CorMedix Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
CRMD
Earnings
- 3/5/26 - Miss
CRMD
Sec Filings
- 3/6/26 - Form 8-K
- 3/5/26 - Form 10-K
- 3/5/26 - Form 8-K
- CRMD's page on the SEC website